Catalio Capital Management

Catalio Capital Management is a New York-based venture capital firm specializing in healthcare and biotechnology investments. Founded in 2020 by George C. Petrocheilos and Dr. R. Jacob Vogelstein, the firm focuses on breakthrough biomedical technologies across private equity and venture capital stages. Catalio has raised over $400 million for its fourth fund, Catalio Nexus Fund IV, which has already invested in 16 companies, including PinkDx and Superluminal Medicines. The firm operates globally with offices in New York, Washington D.C., and London, and collaborates with a network of over 45 venture partners, including Nobel Prize winners and serial scientist-entrepreneurs. Catalio's investment strategy centers on identifying and supporting transformative biomedical companies at all stages, leveraging its scientific expertise and extensive advisor network to evaluate and back companies deeply. The firm has completed more than 20 exits since its founding, including ArriVent BioPharma, Recursion Pharmaceuticals, Thrive Earlier Detection, and Haystack Oncology.

Focus on healthcare and biotechnology sectors, Preference for companies with innovative biomedical technologies, Interest in both private equity and venture capital stages, Global operational scope with offices in New York, Washington D.C., and London, Collaboration with a network of over 45 venture partners, including Nobel Prize winners and serial scientist-entrepreneurs, Investment strategy centers on identifying and supporting transformative biomedical companies at all stages, Leverages scientific expertise and extensive advisor network to evaluate and back companies deeply, Completed more than 20 exits since its founding, including ArriVent BioPharma, Recursion Pharmaceuticals, Thrive Earlier Detection, and Haystack Oncology